可吸收柠檬酸基生物陶瓷装置是否与骨整合相关?一项早期回顾性MRI分析
本研究回顾性分析15例足踝肌腱转位或韧带重建患者,使用柠檬酸基生物陶瓷干涉装置,对13例(25个装置)术后至少2年进行MRI盲法评估。结果显示无骨隧道扩大,21/25装置近完全骨整合,无装置相关临床并发症,但样本量小,证据等级IV。
要点
- 柠檬酸基生物陶瓷装置术后至少2年MRI未见骨隧道扩大。
- 21/25装置沿长轴显示76%–100%骨整合,无装置破裂等不良发现。
- 中位随访36个月无装置相关临床并发症,但样本量小需谨慎解读。
核心结论
- 柠檬酸基热固性聚合物与羟基磷灰石复合装置未出现其他可吸收装置的常见问题。
- 因样本量很小且存在多种局限性,不应基于本研究推荐广泛使用该材料。
研究设计与样本
- 回顾性队列研究,15例足踝肌腱转位或韧带重建患者使用柠檬酸基生物陶瓷干涉装置。
- 13例(25个装置)在术后至少2年(范围2–4年)接受MRI,由两名研究者盲法独立评估。
- 骨隧道扩大通过测量骨隧道内表面与装置螺纹外径间隙宽度(毫米)量化;骨水肿和骨整合采用五点区间量表(0%、0–25%、26–50%、51–75%、76–100%)评估。
- 组内相关系数1.0(间隙宽度),PABAK=0.92(骨水肿和骨整合百分比区间)。
- 证据等级Level IV,治疗性研究。
主要发现
- 所有装置均无 measurable 骨隧道扩大。
- 2个装置显示骨水肿局限于≤25%装置周径。
- 所有装置周围均发生骨整合,21/25装置沿长轴显示76%–100%近完全整合。
- 中位随访36个月,13例可评估患者中无装置相关临床并发症。
临床怎么用
- 对于足踝软组织固定,柠檬酸基生物陶瓷干涉装置在至少2年MRI随访中显示良好的骨整合和低并发症率。
- 鉴于样本量小且为回顾性设计,目前应仅限于研究或严格指征下使用,不宜广泛推广。
局限性
- 样本量很小(15例患者,13例MRI评估,25个装置)。
- 回顾性设计,非对照研究。
- 仅评估足踝部位,随访时间有限(2–4年)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bioresorbable fixation devices may be advantageous because they eliminate the question of whether they ought to be removed, have biomimetic qualities, and minimize artifacts seen on MRI. Most bioresorbable devices utilized during orthopaedic surgery consist of thermoplastic polymers derived from lactic and glycolic acids. These devices are linked to implant-related osteolysis, inflammation, and bone tunnel enlargement, and their integration with surrounding bone is inconsistent. Citregen®, a resorbable composite of a citrate-based thermoset polymer and hydroxyapatite, recently has been approved for use in the United States; yet to date, there are no published studies documenting device-related MRI findings. QUESTIONS/PURPOSES: (1) Was there observable bone tunnel enlargement on MRI at a minimum of 2 years after implantation of a resorbable citrate-based bioceramic device? (2) Were there other observable adverse findings (such as bone marrow edema or device breakage) on MRI at a minimum of 2 years after implantation of a resorbable citrate-based bioceramic device? (3) Did citrate-based bioceramic devices demonstrate integration with surrounding bone on MRI at a minimum of 2 years after implantation? (4) What was the frequency of early clinical complications after soft tissue fixation with citrate-based bioceramic interference devices? METHODS: All 15 patients who underwent tendon transfer or ligament reconstruction in the foot and ankle during a 21-month time period were treated with citrate-based bioceramic interference devices. This group of patients had a median (range) age of 55 years (21 to 75), and 10 were male. Most presented with degenerative or work-related conditions; two had athletic injuries. Two patients were lost to follow-up, and MRI scans performed on 13 patients (25 devices) more than 2 years after surgery were reviewed separately in retrospective, blinded fashion by two investigators. For each device, surrounding bone was assessed for bone tunnel enlargement, which was quantified in millimeters by measuring the width of any gap between the inner surface of the bone tunnel and the outer diameter of the device threads. An intraclass correlation coefficient of 1.0 was achieved, indicating absolute agreement between raters with regard to width of gap measured to the nearest millimeter. The proportion of bone marrow edema abutting the total cross-sectional circumference of each device was quantified using a five-point interval scale (0%, 0% to 25%, 26% to 50%, 51% to 75%, and 76% to 100%). Percentage intervals assessed on the five-point scale demonstrated high interrater reliability (prevalence-adjusted, bias-adjusted kappa [PABAK] = 0.92). Qualitative assessment for other adverse findings, such as cysts, sinus tracts, peridevice fluid, and device breakage, was also performed. The proportion of osseous integration along the long axis of each device was also quantified using a five-point interval scale (0%, 0% to 25%, 26% to 50%, 51% to 75%, and 76% to 100%). Percentage intervals assessed on the five-point scale demonstrated high interrater reliability (PABAK = 0.92). Retrospective chart analysis was used to document the number of complications at the most recent follow-up. RESULTS: There was no measurable bone tunnel enlargement around any of the devices. Two devices showed bone marrow edema limited to 25% or less of device circumference. Osseous integration occurred around all devices, with 21 of 25 implants showing near-complete (76% to 100%) integration along their long axes. Clinically, there were no device-related complications at median follow-up of 36 months in the 13 patients who were accounted for at a minimum of 2 years (range 2 to 4 years). CONCLUSION: In our study of a citrate-based thermoset polymer with hydroxyapatite, common problems associated with other resorbable devices were not seen. Although these findings are promising, our series was very small and had multiple limitations. Therefore, this study should not serve as a basis to recommend widespread use of this material without publication of larger and more rigorous studies that independently replicate our findings. LEVEL OF EVIDENCE: Level IV, therapeutic study.
引用
- Berberian WS, Day J, Schon L, et al. Is a Resorbable Citrate-based Bioceramic Device Associated With Osseous Integration? An Early Retrospective MRI Analysis. Clin Orthop Relat Res. 2026. PMID: 42297353. doi:10.1097/CORR.0000000000004016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。